Notably, the GT-related risk signature demonstrated a higher predictive accuracy for 3-year overall survival compared to several established clinical prognostic factors, including the INSS stage, MYCN status, and clinical high-risk categorization (Figure 5B), suggesting its potential use as a valuable prognostic tool in neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.